TABLE 2.

Adverse event summary

Characteristic	Phase IA			Phase IB (1.5 g)
	Cohort 1 (1.0 g)	Cohort 2 (1.5 g)	Cohort 3 (2.0 g)
No. of participants	9	9	9	9
No. of participants with SAEs	0	0	0	0
No. of participants with unexpected events	0	0	0	0
No. (%) of clinical events	4	7	20	5
Grade 1	4 (100)	3 (43)	17 (85)	5 (100)
Grade 2	0	4 (57)	3 (15)	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0
No. (%) of laboratory events	8	5	11	6
Grade 1	2 (25)	4 (80)	8 (73)	6 (100)
Grade 2	6 (75)	1 (20)	2 (18)	0
Grade 3	0	0	1 (9)	0
Grade 4	0	0	0	0